Guggenheim Highlights Latest Specialty Pharma Short Interest Data (HZNP) (VRX) (PRGO) (SHPG) (AGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant (VRX) Investors Should Be Focused on Earnings Not Upcoming Product Catalysts - Wells Fargo
July 14, 2016 1:29 PM EDTWhile Valeant Pharmaceuticals (NYSE: VRX) continues to avoid trading on fundamentals three potential catalysts lie ahead for the company. Today, Wells Fargo bearish-leaning analyst David Maris provide his thoughts ahead of these events.
The 3 events are:
Friday (7/15) advisory panel documents should become available ahead of next Tuesdays (7/19) FDA advisory panel on brodalumab;next... MoreJefferies Reiterates Buy on Amgen (AMGN) Following FDA Approval of Humira Biosimilar
July 13, 2016 8:24 AM EDTJefferies reiterated a Buy rating and $187.00 price target on Amgen (NASDAQ: AMGN) following the FDA's approval recommendation of AMGN's Humira Biosimilar. The FDA voted unanimously, noting that the totality of the evidence demonstrates biosimilarity of ABP 501 vs. Humira.
Analyst Eun Yang commented, "While... More
RBC Highlights Next Week's Key Events for Valeant Pharma (VRX)
July 13, 2016 8:19 AM EDTRBC affirms Valeant Pharma (NYSE: VRX) at Sector Perform with a price target of $33 as the firm provides a schedule and commentary of what investors should focus on next week for the company.
RBC analyst Douglas Miehm noted:
Upcoming PDUFA dates: Oral Relistor (July 19) and latanoprostene bunod (July 21). Valeant has two PDUFA dates next week. The first, on July 19, is for Oral Relistor for the treatment of opioid-induced constipation. Following the FDA's delay in PDUFA date, we remain confident that Oral Relistor should see approval in or... MoreLong-Time Valeant Pharma (VRX) Holder Sequoia Fund Exits Position
July 13, 2016 6:09 AM EDTValeant Pharma (NYSE: VRX) shares are on watch Wednesday following news that long-time holder Sequoia Fund exited its position.
